Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Marksans Pharma Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199228-03-2013
28-03-2013
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Marksans Pharma Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199226-03-2013
Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE26-03-2013
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Marksans Pharma Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199225-03-2013
Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE25-03-2013
Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE22-03-2013
Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE21-03-2013
Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Mark Saldanha has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE20-03-2013
Settlement of Outstanding Foreign Currency Convertible Bonds
Marksans Pharma Ltd has informed BSE that the Company has entered into a Settlement Agreement with the holders of Foreign Currency Convertible Bonds (FCCBs) for settling USD 26,918,000 worth of FCCBs in principal value.04-03-2013
Financial Results & Limited Review for Dec 31, 2012
Marksans Pharma Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended December 31, 2012.14-02-2013